1JUDGE D P, DIETZ H C. Marian's syndrome[J]. Lancet, 2005, 366 (9501) : 1965-1976.
2VISCONTI R P, BARTH J L, KEELEY F W, et al. Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development[J]. Matrix Biol, 2003, 22(2) : 109-121.
3ISOGAI Z, ONO R N, USHIRO S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibrilassociated protein [J ]. J Biol Chem, 2003, 278 (4) : 2750-2757.
4NEPTUNE E R, FRISCHMEYER P A, ARKING D E, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome[J]. Nat Genet, 2003, 33 (3): 407-411.
5LOEYS B L, CHEN I, NEPTUNE E R, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBRI or TGFBR2[J]. Nat Genet, 2005, 37 (3): 275-281.
6NG C M, CHENG A, MYERS L A, et al. TGF-beta- dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome [J]. J Clin Invest, 2004,114 (11): 1596-1592.
7HABASHI J P, JUDGE D P, HOLM T M, et al. Losartan, an ATI antagonist, prevents aortic aneurysm in a mouse model of Marian syndrome[J]. Science, 2006, 312 (5770): 117-121.
8TIERNEY E S, FEINGOLD B, PRINTZ B F, et al. Betablocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome[J]. J Pediatr, 2007, 150 (1): 77-82.
9YETMAN A T, BORNEMEIER R A, MCCRINDLE B W. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome[J]. Am JCardiol, 2005, 95 (9): 1125-1127.
10DEAN J C. Management of Marfan syndrome[J]. Heart, 2002, 88 (1): 97-103.
